Wolf, Sebastian; Verena, Hoffmann; Florian, Sommer; Matthias, Schrempf; Mingming, Li; Martin, Ryll; Ulrich, Wirth; Matthias, Ilmer; Jens, Werner; Joachim, Andrassy (2022): Effect of Sirolimus vs. Everolimus on CMV-Infections after Kidney Transplantation. A Network Meta-Analysis. Journal of Clinical Medicine, 11 (14): 4216. ISSN 2077-0383
jcm-11-04216-v2.pdf
Die Publikation ist unter der Lizenz Creative Commons Namensnennung (CC BY) verfügbar.
Herunterladen (740kB)
Abstract
(1) Background: Following renal transplantation, infection with cytomegalovirus (CMV) is a common and feared complication. mTOR-inhibitor (mTOR-I) treatment, either alone or in combination with calcineurininhibitors (CNIs), significantly reduces the CMV incidence after organ transplantation. As of now, there is no information on which mTOR-I, sirolimus (SIR) or everolimus (ERL), has a stronger anti-CMV effect. (2) Methods: The current literature was searched for prospective randomized controlled trials in renal transplantation. There were 1164 trials screened, of which 27 could be included (11,655 pts.). We performed a network meta-analysis to analyze the relative risk of different types of mTOR-I treatment on CMV infection 12 months after transplantation compared to CNI treatment. (3) Results: Four different types of mTOR-I treatment were analyzed in network meta-analyses—SIR mono, ERL mono, SIR with CNI, ERL with CNI. The mTOR-I treatment with the strongest anti-CMV effect compared to a regular CNI treatment was ERL in combination with a CNI (relative risk (RR) 0.27, confidence interval (CI) 0.22–0.32, p < 0.0001). The other mTOR-I therapy groups showed a slightly decreased anti-CMV efficacy (SIR monotherapy (mono): RR 0.35, CI 0.22–0.57, p < 0.001; SIR with CNI: RR 0.43, CI 0.29–0.64, p < 0.0001; ERL mono: RR 0.46, CI 0.22–0.93, p = 0.031). (4) Conclusions: The anti-CMV effect of both mTOR-Is (SRL and ERL) is highly effective, irrespective of the combination with other immunosuppressive drugs. Certain differences with respect to the potency against the CMV could be found between SRL and ERL. Data gained from this analysis seem to support that a combination of ERL and CNI has the most potent anti-CMV efficacy.
Dokumententyp: | Artikel (Klinikum der LMU) |
---|---|
Organisationseinheit (Fakultäten): | 07 Medizin > Klinikum der LMU München > Klinik für Allgemeine, Viszeral-, Gefäß- und Transplantationschirurgie |
DFG-Fachsystematik der Wissenschaftsbereiche: | Lebenswissenschaften |
Veröffentlichungsdatum: | 20. Okt 2022 07:50 |
Letzte Änderung: | 07. Dez 2023 12:15 |
URI: | https://oa-fund.ub.uni-muenchen.de/id/eprint/173 |
DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 491502892 |